Modality
Vaccine
MOA
MDM2i
Target
CGRP
Pathway
STING
Asthma
Development Pipeline
Preclinical
Jun 2024
→ Aug 2028
PreclinicalCurrent
NCT06643642
133 pts·Asthma
2024-07→2025-10·Recruiting
NCT05290739
2,708 pts·Asthma
2024-06→2028-08·Recruiting
2,841 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-126mo agoInterim· Asthma
2028-08-032.3y awayInterim· Asthma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2025-10-12 · 6mo ago
Asthma
Interim
2028-08-03 · 2.3y away
Asthma
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06643642 | Preclinical | Asthma | Recruiting | 133 | FEV1 |
| NCT05290739 | Preclinical | Asthma | Recruiting | 2708 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |